One-time Gene Therapy for Sickle Cell Disease
June 03, 2020

Aruvant is developing ARU-1801, a one-time, potentially curative gene therapy for sickle cell disease and β-thalassemia. In an ongoing clinical phase 1/2 study, ARU-1801, administered with only reduced intensity conditioning,
has provided stable reductions in disease burden and opioid dependence.

View Press Release Here